Kiniksa Pharmaceuticals: appoints Ross Moat as president and COO

What happened On Oct 17, 2026, the Compensation Committee of the board of Kiniksa Pharmaceuticals International, plc reported that it appointed Ross Moat as President and Chief Operating Officer, effective immediately. The Committee also approved, effective Jan 1, 2027, an increase in Mr. Moat’s annual base salary to $700,000 from $650,000 and an increase in his annual target bonus to 60% from 55%.

Key details

• Appointment date: Oct 17, 2026; effective immediately.
• Base salary: increased to $700,000 from $650,000, effective Jan 1, 2027.
• Annual target bonus: increased to 60% from 55%, effective Jan 1, 2027.
• Mr. Moat has served at the company since Jun 2019, most recently as EVP, Chief Operating Officer; he oversees the company’s commercial, clinical, regulatory and manufacturing operations. The filing states there are no family relationships between Mr. Moat and any director or executive officer and no related party transactions requiring disclosure under Item 404(a) of Regulation S-K.

Why it may matter The filing reports Item 5.02: Departure of Directors or Certain Officers; Election of Directors, which covers changes in officers and directors and related disclosures. This filing does not show why the insider traded or why the company acted.